Epstein-Barr virus: LMP1 masquerades as an active receptor

Current Biology

Volumn 8, Issue 6, 1998, Pages

  Eliopoulos, Aristides G ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN HERPESVIRUS 4;

EID: 0032510393     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0960-9822(98)70123-x     Document Type: Short Survey

References (18)

1. Kieff E: Epstein-Barr virus and its replication. In Virology. Edited by Fields BC, Knipe DM, Howley PM. New York: Lippincott-Raven Press; 1996:2343-2396.
2. Kaye KM, Izumi KM, Mosialos G, Kieff E: The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 1995, 69:675-683.
3. Huen DS, Henderson SA, Croom-Carter D, Rowe M: The Epstein-Barr virus latent membrane protein 1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995, 10:549-560.
4. Mitchell T, Sugden B: Stimulation of NFκB-mediate transcription by mutant derivatives of the latent protein of Epstein-Barr virus. J Virol 1995, 69:2968-2976.
5. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W: Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 1997, 16:6478-6485.
6. Eliopoulos AG, Young LS: Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998, in press.
7. Mosialos G, Birkenbach M, Yalamanchili R, Van Arsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP-1 engages signalling proteins for the tumour necrosis factor Receptor Family. Cell 1995, 80:389-399.
8. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G: Tumour necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1996, 93:11085-11090.
9. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijner M, Kieff E, Mosialos G: TRAF1, TRAF2 and TRAF3 effect NF-κB activation by an Epstein-Barr virus LMP1 domain important for B lymphocyte transformation. Mol Cell Biol 1996, 16:7098-7108.
10. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS: Epstein-Barr virus-encoded LMP1 and CD40 mediate IL6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 1997, 14:2899-2916.
11. Maniatis T: Catalysis by a multiprotein IκB kinase complex. Science 1997, 278:818-820.
12. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA: Localisation of the major NF-κB-activating site and the sole TRAF3 binding site of LMP1 defines two distinct signalling motifs. J Biol Chem 1997, 272:19777-19784.
13. Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumour necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci USA 1997, 94:12592-12597.
14. Liu Z, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 1996, 87:565-576.
15. Shi C-S, Kehrl JH: Activation of stress-activated protein kinase/cJun N-terminal kinase, but not NF-κB, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway. J Biol Chem 1997, 272:32102-32107.
16. Gires O, Zimber-Strobl U, Gonella R, Ueffing M, Marschall G, Zeidler R, Pich D, Hammerschmidt W: Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997, 16:6131-6140.
17. Floettmann JE, Rowe M: Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerization for NF-κB activation. Oncogene 1997, 15:1851-1858.
18. Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G: A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-κB, and stress-activated protein kinase. J Immunol 1998, 3:1116-1121.